

## Metivier, Jacob

---

**From:** Lopez, Jorge <jorge.lopez@novartis.com>  
**Sent:** Thursday, May 25, 2023 4:43 PM  
**To:** AGO - High Cost Prescription Drugs  
**Subject:** RE: VT Notice of Introduction of New High-Cost Prescription Drugs - Tafinlar & Mekinist

**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

Product name was accidentally changed during spell check in the below message. The correct product name is Tafinlar not "Tailer", thank you

Best,

**Jorge Lopez**  
Manager, Government Pricing

Phone +1 862 7784881  
[jorge.lopez@novartis.com](mailto:jorge.lopez@novartis.com)

**Managed Markets Finance/HCA**  
Novartis Pharmaceuticals  
One Health Plaza  
East Hanover, NJ 07936-1080

---

**From:** Lopez, Jorge  
**Sent:** Thursday, May 25, 2023 4:42 PM  
**To:** 'AGO.highcostprescriptiondrugs@vermont.gov' <AGO.highcostprescriptiondrugs@vermont.gov>  
**Subject:** VT Notice of Introduction of New High-Cost Prescription Drugs - Tafinlar & Mekinist

To the Office of Attorney General:

Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), effective July 1, 2018, when a prescription drug manufacturer introduces a new prescription drug to market at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program, that manufacturer is required to provide certain written information to the Attorney General's Office.

Per section (2)(b) of § 4637 Notice Of Introduction Of New High-Cost Prescription Drugs, Novartis is notifying the Office of the Attorney General in the state of Vermont the Wholesaler Acquisition Cost (WAC) following the line extension/ expanded indication of Tafinlar and Mekinist into the commercial market.

Please see table below and attached:

NDC	Drug Product Description	Introduction to Market	WAC at Introduction
00078-1161-47	Mekinist® (trametinib) for oral solution 4.7MG	Tuesday, May 16, 2023	\$1,548.98
00078-1154-21	Tailer® (dabrafenib) tablets for oral suspension 10MG 210	Tuesday, May 16, 2023	\$3,663.27

Please feel free to contact me if you have any questions and/or require any additional information.

Best,

**Jorge Lopez**

Manager, Government Pricing

Phone +1 862 7784881

[jorge.lopez@novartis.com](mailto:jorge.lopez@novartis.com)

**Managed Markets Finance/HCA**

Novartis Pharmaceuticals

One Health Plaza

East Hanover, NJ 07936-1080